Provides mechanistic and translationally relevant evidence that a nanoparticle combining enhanced brain delivery with ROS elimination and anti-neuroinflammatory effects can ameliorate PD phenotypes, highlighting a promising therapeutic strategy while raising important safety and manganese-toxicity…

By linking vesicle trafficking and immune alterations to specific, druggable-sounding genes (TRAPPC13, COPS5) this study highlights mechanistic hypotheses and patient stratification axes useful for therapeutic target prioritization and follow-up functional validation, though its translational…

This provides a peripheral, inflammation-related biomarker candidate reflecting impaired immunoregulatory capacity in advanced PD that could help stage disease or stratify patients for immune-modulatory approaches, albeit requiring validation and mechanistic follow-up.

Moderately relevant to Parkinson's research because it models how viral-triggered chronic neuroinflammation and neuron loss can drive lasting behavioral deficits and could be used to test anti-inflammatory or neuroprotective strategies, but it lacks PD-specific mechanisms (e.g., alpha-synuclein,…

The work links environmental manganese and viral infection to heightened hippocampal neuroinflammation relevant to PD-related cognitive decline, supporting inflammation as a potential intervention axis even though it lacks direct PD-specific mechanisms or therapeutic candidates.

This paper has minimal direct relevance to Parkinson's therapeutic discovery but highlights the need for accurate systemic diagnosis and multidisciplinary management of complex comorbidities, a tangential consideration for patient selection and safety in neurodegeneration clinical research.

By delivering a quantifiable, scalable preclinical model and objective behavioral readouts, the work enables circuit-level mechanistic studies and screening of interventions for PD visual hallucinations, increasing translational potential despite limited immediate molecular targets.

While not revealing molecular targets, the work highlights a measurable biomechanical biomarker (APA duration) and supports therapeutic strategies aimed at improving postural preparation and executive control (e.g., targeted rehabilitation or neuromodulation) to reduce freezing episodes.

Modulating peptide aggregation with electric fields is an intriguing, nonchemical approach that could conceivably be applied to reduce amyloid-like fibrillation (e.g., alpha-synuclein) relevant to Parkinson's, but this study uses artificial short peptides and lacks disease‑relevant proteins,…

Although it offers little direct mechanistic or druggable insight, the study highlights socioeconomic factors as important confounders for clinical outcomes, trial design, patient stratification, and non-pharmacologic interventions that can influence therapeutic development and access.

By identifying a small endogenous molecule that directly blocks early α‑synuclein LLPS—a process linked to fibril formation—this work provides a concrete, targetable mechanism with repurposing and drug-development potential for Parkinson's disease, though in vivo efficacy and safety remain to be…

This provides Parkinson's drug discovery with prioritized, cell-type-resolved candidate genes (e.g., MAPT in astrocytes and immune/microglial hits) to guide target selection and mechanism-focused follow-up, although direct PD-specific functional validation and therapeutic leads are not yet provided.

By engaging antioxidant, proteostasis and mitophagy mechanisms directly implicated in alpha‑synuclein clearance and mitochondrial dysfunction in Parkinson’s, D‑pinitol is a low‑toxicity, repurposing‑friendly candidate that merits mammalian preclinical evaluation for neuroprotective therapy…

It offers a validated, non-invasive biomarker to detect individuals at increased risk for PD and a plausible avenue for microbiome-targeted interventions or trial enrichment to test neuroprotective strategies in the premanifest phase.

This links a common PD-associated metal‑transporter SNP to microbiome shifts that correlate with disease outcomes, highlighting a potential route for genotype‑stratified microbiome biomarkers or microbiome‑targeted therapies, though causal mechanisms remain to be demonstrated.

By mapping how nanoparticle-based delivery can target PD-relevant processes (e.g., alpha‑synuclein aggregation, inflammation, mitochondrial/lysosomal dysfunction) and summarizing translational hurdles and trials, the paper helps prioritize nanotherapeutic avenues with real clinical development…

The study delivers high‑accuracy CSF biomarker panels for differential diagnosis and points to gut‑brain and membrane lipid metabolic pathways that are actionable for patient stratification, target validation, or repurposing efforts in atypical parkinsonian and related neurodegenerative therapeutic…

By revealing a dopaminergic pathway that drives astrocytic glycolysis via β1-adrenergic signalling, the work highlights a novel metabolic mechanism potentially relevant to Parkinson's disease (where noradrenergic loss may impair astrocyte support) and points to astrocytic β1 signalling and lactate…

Points to modifiable metabolic dysfunction (insulin resistance/glucolipotoxicity) as a clinically measurable predictor of PDD and provides an interpretable risk tool that supports metabolic-targeted therapeutic strategies, though causality is limited by cross-sectional design.

By revealing network-level structural–metabolic decoupling, especially in orbitofrontal–basal ganglia circuits, the work suggests multimodal imaging biomarkers for patient stratification and for tracking or targeting circuit- and metabolism-focused interventions, though it stops short of…

By demonstrating substantially improved CNS delivery of an approved PD dopamine agonist, the work supports a translational route-optimization strategy to enhance symptomatic control and bypass first-pass/GI issues, though it lacks efficacy, safety, and disease‑modifying data.

Pinpoints specific membrane lipid changes as potential PD biomarkers and implicates altered lipid metabolism/membrane integrity in disease progression, offering translational leads for biomarker development or lipid-targeted neuroprotective strategies.

By highlighting a gut‑microbe–based route to degrade a pesticide metabolite linked to Parkinson’s risk, the work suggests microbiome engineering or enrichment could reduce environmental contributors to PD, though it remains purely in silico and needs biochemical and in vivo validation.

Valuable for hypothesis generation because it aggregates environmental exposures that converge on PD-relevant pathways (mitochondria, proteostasis), yet its broad, non-specific synthesis limits immediate translational or drug-discovery impact.

Offers a rigorous, uncertainty-aware computational tool to quantify gut microbiome metabolic interactions and prioritize microbiota-targeted interventions relevant to the gut–brain axis in Parkinson's disease, but it lacks direct PD-specific mechanistic or clinical validation.